| Literature DB >> 35785262 |
Anas Ahmad1,2.
Abstract
In the recent past, nanotechnological advancements in engineered nanomaterials have demonstrated diverse and versatile applications in different arenas, including bio-imaging, drug delivery, bio-sensing, detection and analysis of biological macromolecules, bio-catalysis, nanomedicine, and other biomedical applications. However, public interests and concerns in the context of human exposure to these nanomaterials and their consequential well-being may hamper the wider applicability of these nanomaterial-based platforms. Furthermore, human exposure to these nanosized and engineered particulate materials has also increased drastically in the last 2 decades due to enormous research and development and anthropocentric applications of nanoparticles. Their widespread use in nanomaterial-based industries, viz., nanomedicine, cosmetics, and consumer goods has also raised questions regarding the potential of nanotoxicity in general and reproductive nanotoxicology in particular. In this review, we have summarized diverse aspects of nanoparticle safety and their toxicological outcomes on reproduction and developmental systems. Various research databases, including PubMed and Google Scholar, were searched for the last 20 years up to the date of inception, and nano toxicological aspects of these materials on male and female reproductive systems have been described in detail. Furthermore, a discussion has also been dedicated to the placental interaction of these nanoparticles and how these can cross the blood-placental barrier and precipitate nanotoxicity in the developing offspring. Fetal abnormalities as a consequence of the administration of nanoparticles and pathophysiological deviations and aberrations in the developing fetus have also been touched upon. A section has also been dedicated to the regulatory requirements and guidelines for the testing of nanoparticles for their safety and toxicity in reproductive systems. It is anticipated that this review will incite a considerable interest in the research community functioning in the domains of pharmaceutical formulations and development in nanomedicine-based designing of therapeutic paradigms.Entities:
Keywords: drug delivery; fetal toxicity; multifunctional nanoparticles; nanotoxicology; reproductive toxicology
Year: 2022 PMID: 35785262 PMCID: PMC9240477 DOI: 10.3389/ftox.2022.895667
Source DB: PubMed Journal: Front Toxicol ISSN: 2673-3080
FIGURE 1Diagrammatic representation of various effects of nanomaterials on human and environmental processes (reprinted with permission from Zielińska et al. (2020)).
FIGURE 2Schematic presentation of adverse impacts of engineered nanoparticles on the reproductive health of humans. IUGR, intrauterine growth retardation; LBW, low birth weight; PTD, preterm delivery. Adapted from Brohi et al. (2017) and Tran et al. (2022)
Adverse effects and toxicological implications of various types of nanoparticles in the female reproductive system and stages of fetal development.
| Type of NPs | Size/size range | Dose/concentration | Animals/model | Toxicological outcomes | Reference |
|---|---|---|---|---|---|
| Polyvinyl pyrrolidone–coated silver NPs | 20–50 nm | 0.427, 0.407, and 0.013 mg/kg | Rats | NPs are causing impairing of cognition in the offspring. |
|
| Gold NPs | 10 | 2.85 × 1010 NPs/ml |
| NPs are found to be affecting steroidogenetic capacities by the granulosa cells in culture media after trespassing through the granulosa cell membranes. |
|
| Silver nanoparticles | 14 nm | 50 nM | Mice | Inner cellular mass was subjected to the induced apoptosis, and embryonic growth shows trophectoderm. |
|
| Gold NPs | 13 | 0.9–7.2 μg/g body weight | Mice | NPs get accumulated in the placental and fetal tissues. |
|
| Silver nanoparticles | 35 nm | 1.69–2.21 mg/kg | Rats | NPs show appearance in the fetal growth. |
|
| Gold NPs | 20 | 1 nm for 48 or 72 h |
| NPs cause the alteration of almost 19 genetic makeups in the fibroblast cells of the lungs of the fetus. |
|
| Silver nanoparticles | 8 nm | 250 mg/kg | Rats | Pups’ tissues exhibit NP accumulation. |
|
| Gold NPs | 20 & 50 | 0.01% | Mice | NPs can travel through the placenta through endocytic vesicular transportation |
|
| Silver nanoparticles | – | 0.001–100 μg/ml |
| NPs show interference in the reproductive tissue function and alter levels of E2 and P4. |
|
| Gold NPs | 3, 13 & 32 nm | 0.9 μg/g body weight | Mice | NPs are found to be enhancing the inflammation of uterine tissues and get accumulated in fetal tissues |
|
| Silver nanoparticles | – | 0.09–1.0 mg/ml |
| Intervention by NPs in proliferative pathways and cause apoptotic implications in granulosa cell lines of pork ovaries |
|
| Gold, silver, and gold-silver alloy | 6 and 20 nm | 0.66 g/L for alloy, 2.5 g/L for silver, and 0.5 g/L for gold | Pigs’ | NPs are found to be inhibiting the maturation of oocytes, and toxic impacts are increased by the NPs of alloys. |
|
| Silver nanoparticles | 35 nm | 1.69–2.21 mg/kg | Mice | NPs travel in the mother’s breast milk and get accumulated in the developing embryos |
|
| Titanium dioxide NPs | 5.5 nm | 10 mg/kg | Mice | Initiation of premature oogenesis and causing the apoptotic cell death in ovarian cells, enhancing the atresia in primary and secondary follicular developmental stages |
|
| Silver nanoparticles | 55 nm | 0.2–20 mg/kg | Rats | Nanoparticle demons |
|
| Titanium dioxide NPs | 25 nm | -- |
| Deformation of follicular growth and inhibition of the maturation of oocytes |
|
| Silver nitrate NPs | 55 nm | 20 mg/kg | Rats | NPs damage neurons in the hippocampal regions of the brains of both adults and offspring. |
|
| Titanium dioxide NPs | 13–27 nm | 1–5 μg/ml | Chinese hamster ovary cell line | Genotoxic and cytotoxic outcomes |
|
| Cadmium oxide NPs | 11–15 nm | 100 or 230 µg | Mice | Placental toxic reactions |
|
| Silver or silver nitrate NPs | 10 nm | 66 mg/kg | Mice | NPs caused hampering of the growth of embryos |
|
| Titanium dioxide NPs | -- | 2.5, 5, and 10 mg/kg body weight | Mice | Alteration in the expressions of relevant ovarian genes in a concentration-dependent manner |
|
| Titanium dioxide NPs | -- | 0.001–100 μg/ml |
| Alteration in the levels of P4 and E2 and interference in reproductive system functions |
|
| Titanium dioxide NPs | 50 nm | 1 μg/ml | Mice | NPs crossed the placental barrier and hampered the central nervous system development in the fetus |
|
| Titanium dioxide NPs | 10 nm | 100 mg/kg body weight | Rats | NPs exerted neurotoxicity in the brains of neonates and adults |
|
| Titanium dioxide NPs | ∼100 nm | 100 mg/kg body weight | Rats | Induction of apoptotic phenomena and reduction in neurogenesis |
|
| Titanium dioxide NPs | 35 nm | 0.8 mg per animal | Mice | Accumulation of NPs in the brain, placental trophoblasts, and liver of the fetus |
|
| Titanium dioxide NPs | 4 nm | 88–108 m2/gm |
| Placental toxicities |
|
| Aluminum oxide NPs | 9–47 nm | 1–25 μg/ml | Chinese hamster ovary cell line | Cytotoxic and genotoxic effects |
|
| Cerium oxide NPs | 35 nm | 100 µm | Mice | Adverse reactions on oocytes |
|
| Cerium oxide NPs | 35 nm | 10 & 100 µm | Mice | NPs got aggregated and accumulated in follicular cells by the endocytotic mechanism and showed distribution in zona pellucida of oocyte cells |
|
| Zinc oxide NPs | ∼100 nm | 500 mg/kg | Rats | Reduction in the numbers of live-born pups and enhancement of fetal repsorptive phenomena |
|
| Zinc oxide NPs | ∼20 nm | 50 or 100 mg/kg | Hens | Inflammatory responses, ROS production, and disturbances in the signaling pathway |
|
| Polyethylene imine and PAA-coated iron oxide NPs | 28–30 nm | 50 mg/kg body weight | Mice | NPs lead to the death of the fetus. |
|
| Alpha-iron oxide NPs | 50 & 70 nm | 100 μg/ml |
| Oxidative stress and cellular death |
|
| Cadmium oxide NPs | 11–15 nm | 100 and 230 mg/m3 | Mice | NPs show accumulation in placental tissues and an increase in the weight of the fetus. |
|
| Silver NPs | 5–70 nm | 0.2 & 2 mg/kg | Mice | NPs caused neurobehavioral impairments in the offspring. |
|
| Copper oxide NPs | 4 nm | 40–44 m2/g |
| Reduced cell viabilities and reduction in levels of human chorionic gonadotropins |
|
FIGURE 3Schematic representation of the toxicological effects of nanoparticles in pregnancies and fetal developmental stages. Various factors affect the toxicities of nanoparticles which include their shapes, sizes, dosage formulations, shape, surface charge distributions, nanomaterial types, and various surface coating. Once the nanoparticles get entry into the pregnant woman’s body via inhalation, injections, ingestion, or skin penetrations, maternal toxicity stresses including but not limited to reactive oxygen species inflammatory conditions, and apoptotic cell death and endocrinal dyscrasias get induced. During these pregnancy conditions, nanoparticles then may cross placental barriers and can get diffused into fetal tissues by the passive diffusion mechanisms or through endocytotic pathways. These toxicological outcomes of nanoparticles may further initiate inflammation in fetal tissues, apoptotic processes, genotoxicological reactions, cytotoxicities, lower body weights, reproductional deficiencies, neuronal damages, and immunodeficiencies, among various other processes that may culminate in abnormal fetal developmental processes or sometimes fetal death (reprinted with permission from (Hou and Zhu, 2017).
FIGURE 4Potential fetal toxicological implications of various types of nanoparticles. Nanoparticle characteristics viz., hydrodynamic diameter (particle) size, surface morphologies, and their composition; other chemistries play significant roles and regulate the fetal toxicity after the maternal exposure to nanoparticles during pregnancy. Furthermore, maternal circumstances and routes of nanoparticles’ exposure critically control the nanoparticle-induced fetal anomalies (reproduced with permission from (Teng et al., 2021).